Compare Equinor ASA (EQNR) vs GE HealthCare Technologies Inc. Common Stock (GEHC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinor ASA vs GE HealthCare Technologies Inc. Common Stock — how do they compare? Equinor ASA trades at $44.94 (market cap $107.46B), while GE HealthCare Technologies Inc. Common Stock trades at $68.6 (market cap $30.93B). The key difference: Equinor ASA is far larger — about 3.5× GE HealthCare Technologies Inc. Common Stock's market cap, and Equinor ASA pays the higher dividend (3.44%). Which is the better fit depends on your goals.
| EQNR | GEHC | |
|---|---|---|
Market Cap | $107.46B | $30.93B |
Volume | 3,758,208 | 5,033,451 |
Sector | Energy | Health |
52-Week High | $45.75 | $88.16 |
52-Week Low | $22.41 | $59.48 |
Typical Hold Time | 59 Days | — |
Enterprise Value | $116.16B | $39.39B |
Dividend Yield | 3.44% | 0.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EQNR trades at $45.02, up 2.46% today and near its 52-week high of $45.84. The stock shows strong technical momentum with bullish moving averages and recent earnings beats in Q4 2025 and Q1 2026. Valuation metrics appear attractive with P/E of 12.2 and EV/EBITDA of 2.47. Recent news highlights expansion in LNG operations and carbon capture projects, positioning the company for growth in energy transition markets.
EQNR presents a compelling value opportunity with significant upside to the $87.50 consensus price target. Strong cash flow generation and strategic LNG expansion provide fundamental support, though declining profit margins and energy price volatility represent key risks. Analyst sentiment leans bullish with 30% buy ratings, suggesting confidence in the company's transition strategy and operational execution.
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →
